Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 4/20 | 0.56 |
| ▸ | CSF1R | P07333 | 6/20 | 0.53 |
| ▸ | EGFR | P00533 | 5/20 | 0.50 |
| ▸ | BTK | Q06187 | 2/20 | 0.48 |
| ▸ | RAF1 | P04049 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | AURKA | O14965 | 1/20 | 0.45 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21484289 | 0.93 | EGFR (0.50) | JAK3CSF1REGFRBTK | |
| SCHEMBL21484353 | 0.92 | EGFR (0.49) | JAK3CSF1REGFRBTK | |
| SCHEMBL21516226 | 0.91 | JAK3 (0.49) | JAK3CSF1REGFRBTKKCNH2 | |
| SCHEMBL21484328 | 0.90 | EGFR (0.47) | JAK3CSF1REGFRBTKRAF1 | |
| SCHEMBL30294159 | 0.90 | EGFR (0.47) | JAK3CSF1REGFRBTK | |
| SCHEMBL21484330 | 0.90 | EGFR (0.47) | JAK3CSF1REGFRBTK | |
| SCHEMBL29538631 | 0.89 | JAK3 (0.55) | JAK3CSF1REGFRBTKKCNH2 | |
| SCHEMBL21484358 | 0.89 | JAK3 (0.55) | JAK3CSF1REGFRBTKKCNH2 | |
| SCHEMBL21484311 | 0.87 | EGFR (0.47) | JAK3CSF1REGFRBTKKCNH2 | |
| SCHEMBL21484322 | 0.87 | BTK (0.56) | JAK3CSF1REGFRBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110072865-B | Pyrrolo-aromatic heterocyclic compounds, preparation method and medical application thereof | 中国医药研究开发中心有限公司 | 2022-02-11 | — | — | CN | claimed |
| EP-3556761-B1 | PYRROLO-AROMATIC HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | THE NATIONAL INSTITUTES OF PHARMACEUTICAL RES AND DEVELOPMENT NIP (CN) | 2021-03-03 | — | — | EP | claimed |
| US-20200062749-A1 | PYRROLO-AROMATIC HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | THE NATIONAL INSTITUTES OF PHARMACEUTICAL RESEARCH AND DEVELOPMENT (NIP) (CN) | 2020-02-27 | — | — | US | claimed |
| US-11608334-B2 | Pyrrolo-aromatic heterocyclic compound, preparation method therefor, and medical use thereof | The National Institutes of Pharmaceutical R&D Co., Ltd. (CN) | 2023-03-21 | — | — | US | disclosed |
| CN-110072865-B | Pyrrolo-aromatic heterocyclic compounds, preparation method and medical application thereof | 中国医药研究开发中心有限公司 | 2022-02-11 | — | — | CN | disclosed |
| EP-3556761-B1 | PYRROLO-AROMATIC HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | THE NATIONAL INSTITUTES OF PHARMACEUTICAL RES AND DEVELOPMENT NIP (CN) | 2021-03-03 | — | — | EP | disclosed |
| EP-3556761-B1 | PYRROLO-AROMATIC HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | THE NATIONAL INSTITUTES OF PHARMACEUTICAL RES AND DEVELOPMENT NIP (CN) | 2021-03-03 | — | — | EP | disclosed |
| US-20200062749-A1 | PYRROLO-AROMATIC HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | THE NATIONAL INSTITUTES OF PHARMACEUTICAL RESEARCH AND DEVELOPMENT (NIP) (CN) | 2020-02-27 | — | — | US | disclosed |
| US-20200062749-A1 | PYRROLO-AROMATIC HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | THE NATIONAL INSTITUTES OF PHARMACEUTICAL RESEARCH AND DEVELOPMENT (NIP) (CN) | 2020-02-27 | — | — | US | disclosed |
| EP-3556761-A1 | PYRROLO-AROMATIC HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | The National Institutes Of Pharmaceutical Research (CN) | 2019-10-23 | — | — | EP | disclosed |
| EP-3556761-A1 | PYRROLO-AROMATIC HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | The National Institutes Of Pharmaceutical Research (CN) | 2019-10-23 | — | — | EP | disclosed |
| WO-2018088780-A1 | NOVEL PYRROLOPYRIMIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11608334-B2 | Pyrrolo-aromatic heterocyclic compound, preparation method therefor, and medical use thereof | BTK, SYK, ITK | JAK3 33/4885CSF1R 1471/4885EGFR 1705/4885 |
| US-20200062749-A1 | PYRROLO-AROMATIC HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | BTK, SYK, ITK | JAK3 33/4885CSF1R 1471/4885EGFR 1705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.